“These autosomal diseases, from an inheritance standpoint, affect men and women equally, but because of their impact on the gynecological system and menses, women are often affected much more than men," hematologist Donna DiMichele, MD, explains.
By Deena Beasley (Reuters) - High cost, logistical issues and the prospect of potential treatment advances are holding back adoption of the first gene.
High cost, logistical issues and the
prospect of potential treatment advances are holding back
adoption of the first gene therapies for hemophilia, experts
said this week during the American Society.
A study found that negative experiences and concern for future children's health drive hemophilia carriers to choose prenatal tests, with cognitive factors playing a role.
In hemophilia cases where there is uncertainty, especially when your factor level is near the 50% cutoff, genetic testing becomes important, Ragni says.